Abstract Background In the ARISTOTLE (Apixaban for Reduction in Stroke and Other
Thromboembolic Events in Atrial Fibrillation) trial, patients with atrial fibrillation and≥ 2 dose …

Background: Effective prophylaxis and treatment of thromboembolic disorders remain
suboptimal in many healthcare systems, partly owing to limitations of traditional …

The new oral anticoagulants may prove to be one of the most significant innovations in
clinical practice in the past 60 years. Apixaban and rivaroxaban are specific inhibitors of …

Background: Apixaban is a direct oral anticoagulant, which inhibits factor Xa. It has
demonstrated clinical efficacy in prevention of stroke and systemic embolism in adult …

Background—Apixaban is approved for the prevention of stroke and systemic embolism in
patients with nonvalvular atrial fibrillation. However, the Apixaban for Reduction in Stroke …

Venous thromboembolic disease, including deep vein thrombosis and pulmonary embolism,
is a cause of significant mortality and morbidity. For several decades, anticoagulant options …

Atrial fibrillation (AF) is associated with increased risk of stroke that can be attenuated with
vitamin K antagonists (VKAs). Vitamin K antagonist use is limited, in part, by the high …

Introduction Apixaban is an oral direct factor Xa inhibitor developed for the prophylaxis and
treatment of thromboembolic disorders. Laboratory monitoring is not necessary, but the …

Aim Apixaban is an oral factor X a inhibitor approved for stroke prevention in atrial fibrillation
and thromboprophylaxis in patients who have undergone elective hip or knee replacement …

Following major orthopaedic surgery, guidelines usually recommend continued
thromboprophylaxis after hospitalisation. The availability of an effective oral anticoagulant …